Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Kezar Life Sciences Inc (KZR)

Kezar Life Sciences Inc (KZR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 625,306
  • Shares Outstanding, K 60,416
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,630 K
  • 60-Month Beta 0.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.45
Trade KZR with:

Options Overview Details

View History
  • Implied Volatility 79.39% ( -14.29%)
  • Historical Volatility 56.38%
  • IV Percentile 7%
  • IV Rank 4.03%
  • IV High 476.54% on 06/16/22
  • IV Low 62.72% on 09/03/21
  • Put/Call Vol Ratio 13.10
  • Today's Volume 141
  • Volume Avg (30-Day) 528
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 16,438
  • Open Int (30-Day) 21,562

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.30
  • Prior Year -0.28
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.29 +11.41%
on 08/01/22
10.81 -4.26%
on 08/08/22
+0.23 (+2.27%)
since 07/12/22
3-Month
4.30 +140.42%
on 06/13/22
11.02 -6.08%
on 06/28/22
+4.83 (+87.50%)
since 05/12/22
52-Week
4.30 +140.42%
on 06/13/22
18.55 -44.20%
on 03/18/22
+4.50 (+76.92%)
since 08/12/21

Most Recent Stories

More News
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial...

KZR : 10.35 (+6.05%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that,...

KZR : 10.35 (+6.05%)
Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?

The mean of analysts' price targets for Kezar Life Sciences, Inc. (KZR) points to an 81.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

KZR : 10.35 (+6.05%)
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment...

KZR : 10.35 (+6.05%)
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference

Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen...

KZR : 10.35 (+6.05%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 10.35 (+6.05%)
Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain...

MRTX : 86.37 (+7.36%)
BBC : 28.63 (+4.95%)
KZR : 10.35 (+6.05%)
RPTX : 11.93 (-2.29%)
DAWN : 26.57 (+8.45%)
LYEL : 7.31 (+1.67%)
Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 135.4% in Kezar Life Sciences, Inc. (KZR). While the effectiveness of this highly sought-after metric is questionable,...

KZR : 10.35 (+6.05%)
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More

Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.

GILD : 62.96 (+0.82%)
EPZM : 1.4700 (-1.34%)
IPSEY : 25.2999 (-2.99%)
KZR : 10.35 (+6.05%)
STRO : 7.09 (+4.26%)
Why Kezar Life Sciences Stock Is Crushing It Today

A positive phase 2 data readout is lighting a fire underneath the biotech's shares today.

KZR : 10.35 (+6.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South...

See More

Key Turning Points

3rd Resistance Point 11.19
2nd Resistance Point 10.93
1st Resistance Point 10.64
Last Price 10.35
1st Support Level 10.10
2nd Support Level 9.84
3rd Support Level 9.55

See More

52-Week High 18.55
Fibonacci 61.8% 13.11
Fibonacci 50% 11.43
Last Price 10.35
Fibonacci 38.2% 9.75
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar